Fantridone

Fantridone

SCHEMBL1683047

CN(C)CCCn1c(=O)c2ccccc2c2ccccc21

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 4/20 0.69
▸ RORA P35398 4/20 0.69
▸ RORC P51449 4/20 0.69
▸ RORB Q92753 4/20 0.69
▸ HTR3A P46098 1/20 0.61
▸ TOP2A P11388 2/20 0.60
▸ CYP2D6 P10635 1/20 0.59
▸ RXRA P19793 1/20 0.59
▸ MPO P05164 4/20 0.57
▸ XDH P47989 2/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ TDP1 Q9NUW8 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ JAK2 O60674 1/20 0.54
▸ JAK1 P23458 1/20 0.54
▸ TYK2 P29597 1/20 0.54
▸ JAK3 P52333 1/20 0.54
▸ CHRM2 P08172 1/20 0.53
▸ HTR1A P08908 1/20 0.53
▸ CHRM5 P08912 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fantridone SCHEMBL124109 0.98 PGR (0.68) PGRRORARORCRORBHTR3A
SCHEMBL541688 0.87 CYP2D6 (0.74) HTR3ATOP2ACYP2D6MPOXDH
SCHEMBL29907915 0.87 CYP2D6 (0.74) HTR3ATOP2ACYP2D6MPOXDH
SCHEMBL10702688 0.84 SLC6A4 (0.64) HTR3ATOP2ACYP2D6RXRAMPO
SCHEMBL14141960 0.82 RORA (1.00) PGRRORARORCRORBALDH1A1
SCHEMBL3257738 0.81 RORA (0.90) PGRRORARORCRORBALDH1A1
SCHEMBL13863964 0.80 TDP1 (0.62) PGRRORARORCRORBTOP2A
SCHEMBL6219453 0.79 CYP2D6 (0.65) HTR3ATOP2ACYP2D6CHRM2HTR1A
SCHEMBL9043386 0.79 RORA (0.71) PGRRORARORCRORBALDH1A1
SCHEMBL8831732 0.78 RORA (0.69) PGRRORARORCRORBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161243-A1 MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS THE SCRIPPS RESEARCH INSTITUTE 2025-05-22 — — US claimed
US-20240307393-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT NATIONAL CANCER CENTER (KR) 2024-09-19 — — US claimed
EP-4368183-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT National Cancer Center (KR) 2024-05-15 — — EP claimed
CN-117597126-A Pharmaceutical composition for preventing or treating cancer comprising CDK4/6 inhibitor and tricyclic antidepressant 国立癌症中心 2024-02-23 — — CN claimed
WO-2023282544-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT 국립암센터 2023-01-12 — — WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 — — WO claimed
EP-0174342-B1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1989-12-20 — — EP claimed
US-20250161243-A1 MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS THE SCRIPPS RESEARCH INSTITUTE 2025-05-22 — — US disclosed
US-20240307393-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT NATIONAL CANCER CENTER (KR) 2024-09-19 — — US disclosed
EP-4368183-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT National Cancer Center (KR) 2024-05-15 — — EP disclosed
EP-0174342-B1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1989-12-20 — — EP disclosed
US-4771059-A CENTRAL NERVOUS SYSTEM UNIVERSITY OF FLORIDA (US) 1988-09-13 — — US disclosed
EP-0174342-A1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. UNIV FLORIDA (US) 1986-03-19 — — EP disclosed
WO-1985003937-A1 BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES UNIVERSITY OF FLORIDA (US) 1985-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161243-A1 MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS MEF2D, TEAD2, TEAD1 PGR 4761/4885RORA 479/4885RORC 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback